What is Leerink Partnrs’ Forecast for Quanterix Q3 Earnings?

Quanterix Co. (NASDAQ:QTRX) – Research analysts at Leerink Partnrs lifted their Q3 2024 earnings per share (EPS) estimates for Quanterix in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.19) per share for the quarter, up from their previous forecast of ($0.20). The consensus estimate for Quanterix’s current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix’s Q4 2024 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS and Q4 2025 earnings at ($0.21) EPS.

Several other brokerages have also recently weighed in on QTRX. Scotiabank decreased their price target on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a research report on Monday, August 12th. TD Cowen boosted their price objective on Quanterix from $13.50 to $16.00 and gave the stock a “hold” rating in a report on Wednesday.

Quanterix Stock Down 4.0 %

Shares of QTRX opened at $11.44 on Friday. The business’s 50-day moving average price is $12.95 and its 200-day moving average price is $13.97. Quanterix has a twelve month low of $10.50 and a twelve month high of $29.70. The stock has a market cap of $439.07 million, a PE ratio of -10.90 and a beta of 1.36.

Insider Transactions at Quanterix

In other news, Director David R. Walt bought 47,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was acquired at an average price of $13.29 per share, with a total value of $624,630.00. Following the completion of the purchase, the director now directly owns 1,487,342 shares in the company, valued at $19,766,775.18. This represents a 3.26 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 6.90% of the stock is owned by insiders.

Institutional Trading of Quanterix

Several hedge funds and other institutional investors have recently bought and sold shares of QTRX. Easterly Investment Partners LLC boosted its stake in Quanterix by 779.9% in the second quarter. Easterly Investment Partners LLC now owns 692,746 shares of the company’s stock worth $9,151,000 after buying an additional 614,012 shares in the last quarter. Portolan Capital Management LLC boosted its stake in Quanterix by 31.4% in the third quarter. Portolan Capital Management LLC now owns 2,520,686 shares of the company’s stock worth $32,668,000 after buying an additional 602,656 shares in the last quarter. Farallon Capital Management LLC boosted its stake in Quanterix by 156.0% in the first quarter. Farallon Capital Management LLC now owns 471,000 shares of the company’s stock worth $11,097,000 after buying an additional 287,000 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Quanterix in the second quarter worth approximately $3,389,000. Finally, Envestnet Asset Management Inc. boosted its stake in Quanterix by 2,261.8% in the second quarter. Envestnet Asset Management Inc. now owns 209,731 shares of the company’s stock worth $2,771,000 after buying an additional 200,851 shares in the last quarter. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.